ログイン
ランキング
お知らせ
ログイン
文献詳細
増大特集 あしたのアルツハイマー病治療
文献概要
アミロイドPETはアルツハイマー病（AD）に本質的なアミロイド病理を非侵襲的に可視化することができ，最早期のバイオマーカーとして，病態探索研究や治療薬開発に欠かせない診断技術である。アミロイド陽性所見に基づいて早期あるいは前臨床期AD被験者を選択できるようになり，臨床研究や治験の歩みが加速した。アミロイドPETはタウやαシヌクレインの可視化技術の実用化と合わせ，非AD疾患の病態研究への貢献も期待される。
参考文献
1)Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319, 2004
2)McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011
3)Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 7: 270-279, 2011
4)Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, et al: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7: 367-385, 2011
F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med 54: 880-886, 2013
6)Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, et al: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11: 669-678, 2012
7)Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, et al: Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 72: 287-294, 2015
8)Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, et al: Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement 11: 964-974, 2015
C-Pittsburgh compound B PET and postmortem neuropathology. Curr Alzheimer Res 12: 278-286, 2015
C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 138: 1370-1381, 2015
11)石井賢二: アルツハイマー病研究におけるアミロイドPET. Brain Nerve 62: 757-767, 2010
C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging 44: 850-857, 2017
C］PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452, 2006
C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680, 2008
15)Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, et al: Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. Brain 132: 1310-1323, 2009
16)Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, et al: Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74: 905-913, 2013
17)Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al; APOE and Alzheimer Disease Meta Analysis Consortium: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278: 1349-1356, 1997
18)Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, et al: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31: 1275-1283, 2010
19)Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al: Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 6820-6825, 2009
20)Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al: APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131, 2010
21)Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, et al: Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313: 1924-1938, 2015
22)Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, et al: Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313: 1939-1949, 2015
23)Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, et al: Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12: 357-367, 2013
24)Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, et al: Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46: 1688-1697, 2008
25)Sojkova J, Resnick SM: In vivo human amyloid imaging. Curr Alzheimer Res 8: 366-372, 2011
26)Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, et al: Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 133: 512-528, 2010
27)Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, et al: Relationship between memory performance andβ-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 10: 141-144, 2012
28)Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, et al: Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 69: 1032-1042, 2011
29)Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, et al: Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134: 1635-1646, 2011
30)Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, et al: Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 71: 792-797, 2012
31)Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al: Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78: 477-484, 2012
32)Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, et al: Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70: 903-911, 2013
33)Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, et al: Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLOS ONE 8: e58816, 2013［doi: 10.1371/journal.pone.0058816］
34)Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, et al: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465, 2008
ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349, 2007
36)Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011
37)Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, et al: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9: 1118-1127, 2010
38)Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, et al: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13: 614-629, 2014
39)Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, et al: NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44: 1-8, 2016
40)Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, et al: Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurology 86: 50-58, 2016
41)Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, et al: Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62: 229-234, 2007
42)Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, et al: PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 130: 2607-2615, 2007
43)Ly JV, Rowe CC, Villemagne VL, Zavala JA, Ma H, et al: Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage. Ann Neurol 68: 959-962, 2010
C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 74: 487-493, 2010
45)Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, et al: Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Arch Neurol 68: 1461-1466, 2011
46)Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, et al: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathol Commun 4: 130, 2016［doi: 10.1186/s40478-016-0399-z］
47)Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, et al: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79: 229-236, 2012
48)Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, et al: A new amyloid β variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63: 377-387, 2008
49)Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, et al: The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11: 1-15. e1-4, 2015［doi: 10.1016/j.jalz.2014.07.003］
50)Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333, 2014
51)Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, et al: Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12: 110-120, 2016
52)Sevigny J, Suhy J, Chiao P, Chen T, Klein G, et al: Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis Assoc Disord 30: 1-7, 2016
C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9: 363-372, 2010
54)Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, et al: Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69: 198-207, 2012
55)Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, et al: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537: 50-56, 2016
56)厚生労働省研究班「アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究」, 日本核医学会, 日本認知症学会, 日本神経学会: アミロイドPETイメージング剤合成装置の適正使用ガイドライン第1版, 2015 http://www.jsnm.org/japanese/15-06-09
57)Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, et al: Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 27: 4-15, 2013
58)Herscovitch P: Amyloid imaging coverage with evidence development and the IDEAS study. J Nucl Med 56: 20N, 2015
59)Hardy J: Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9 (3 Suppl): 151-153, 2006
60)Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, et al: Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128: 755-766, 2014
61)Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, et al: Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84: 508-515, 2015
62)Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, et al: PART is part of Alzheimer disease. Acta Neuropathol 129: 749-756, 2015
掲載誌情報
